enVVeno Medical Corporation (NASDAQ:NVNO) filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing a net loss of $4,367 thousand for the third quarter and total assets of $19,489 thousand as of that date.

Key Highlights

  • Q3 2026 net loss: $4,367 thousand, compared with $4,539 thousand in Q3 2025, according to the filing.
  • Nine-month net loss: $11,816 thousand for the nine months ended September 30, 2026, versus $15,736 thousand for the same period in 2025.
  • Cash and cash equivalents: $2,585 thousand as of September 30, 2026, down from $3,065 thousand at December 31, 2025.
  • Short-term investments: $15,887 thousand as of September 30, 2026, compared with $25,147 thousand at December 31, 2025.
  • Accumulated deficit: $183,143 thousand as of September 30, 2026, up from $171,327 thousand at December 31, 2025.
  • Shares outstanding: 694,826 shares of common stock as of October 27, 2026, with 695 thousand shares issued and outstanding at quarter end.
  • ATM offering proceeds: $313 thousand raised net of fees through At-the-Market offering during the nine months ended September 30, 2026.

enVVeno Medical Reports Q3 2026 Financial Results and Liquidity Position

According to the filing, enVVeno Medical Corporation reported operating expenses of $4,534 thousand for the three months ended September 30, 2026, consisting of $2,876 thousand in research and development expenses and $1,658 thousand in selling, general and administrative expenses. This compares with total operating expenses of $4,883 thousand in the same quarter of 2025, which included $2,585 thousand in research and development and $2,298 thousand in selling, general and administrative expenses.

For the nine months ended September 30, 2026, the filing reported a loss from operations of $12,392 thousand, compared with $16,886 thousand for the nine months ended September 30, 2025. Other income for the nine-month period included $621 thousand in realized gains from sales of trading securities and $47 thousand in interest income, partially offset by $88 thousand in unrealized losses from trading securities, according to the disclosure. Net cash used in operating activities was $9,965 thousand for the nine months ended September 30, 2026, compared with $12,125 thousand in the prior-year period.

The balance sheet as of September 30, 2026 showed total stockholders' equity of $16,900 thousand, reduced from $27,130 thousand at December 31, 2025. The company reported stock-based compensation of $1,274 thousand for the nine months ended September 30, 2026. The filing also notes the effect of a reverse stock split, which reduced additional paid-in capital by $1 thousand during the nine-month period. Net loss per basic and diluted common share was $(6.29) for Q3 2026 and $(17.51) for the nine months ended September 30, 2026, based on weighted average shares of 694 thousand and 675 thousand, respectively.

What Was Disclosed

enVVeno Medical Corporation filed a Form 10-Q for the quarter ended September 30, 2026, reporting a quarterly net loss of $4,367 thousand, total assets of $19,489 thousand, and cash and short-term investments of $18,472 thousand combined, with an accumulated deficit of $183,143 thousand.